Special Issue "Proton Therapy for CNS Tumors"
Deadline for manuscript submissions: 15 June 2022.
Interests: radiation oncology; proton beam therapy; CNS tumors; sarcomas; pediatric malignancies; quality assurance in radiotherapy; late effects and quality of life
Radiotherapy is an important and highly effective part of modern multimodality management of CNS tumors. However, radiotherapy is known to cause a broad range of adverse effects, potentially having a significant negative impact on quality of life. Thus, strategies that mitigate late effects are needed. With regard to radiotherapy, techniques are attractive when able to better protect normal tissue and critical organs of risk. Due to its particular physical characteristics, Proton therapy (PT) can achieve high dose conformality to the target volume while sparing normal tissue. Important technological advances have managed to make PT more robust and deliverable to a huge variety of tumor entities. PT is often preferred in tumors sites in the vicinity of particularly vulnerable tissue and in tumors requiring high radiation doses. Therefore, CNS and base of skull tumors of the CNS are the predominant diagnoses in the majority of proton facilities and clinical evidence is increasing.
This Special Issue on proton therapy for CNS tumors will highlight the role of PT in CNS tumors, covering various clinical, physical, and biological aspects.
Prof. Dr. Beate Timmermann
Dr. Julie A. Bradley
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- proton therapy
- brain tumors
- late effects
- quality of life